Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
Eisai CEO Haruo Naito on March 25 set out a global sales target of 250-280 billion yen for his company’s Alzheimer’s therapy Leqembi (lecanemab) in FY2027, which it positions as a milestone year en route to its goal of achieving…
To read the full story
Related Article
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Eisai Hits Record Sales as Leqembi Revenue Nearly Doubles in FY2025
May 18, 2026
- Leqembi Sales Soar 153% in H1 FY2025; Eisai Pins Hopes on Self-Injector, Blood Tests
November 6, 2025
- Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
- Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
October 18, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
BUSINESS
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Nxera to Earn US$10 Million Milestone as Alzheimer’s Candidate Moves to PII
August 27, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…